Targeted nanoparticles for pediatric leukemia therapy

Frontiers in Oncology

Volumn 4 MAY, Issue , 2014, Pages

  Basha, Riyaz ^a,b   Sabnis, Nirupama ^b   Heym, Kenneth ^c   Bowman, W Paul ^a,c   Lacko, Andras G ^b  

^a University of North Texas Health Science Center   (United States)

^b UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

^c Risk Evaluation to Achieve Cardiovascular Health   (United States)

Author keywords

Drug delivery systems; High density lipoprotein; Leukemia; Nanoparticles; Targeting

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; DRUG CARRIER; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; NANOPARTICLE; PACLITAXEL; VINCRISTINE SULFATE;

CHILDHOOD LEUKEMIA; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG UPTAKE; HUMAN; MOLECULARLY TARGETED THERAPY; PHILADELPHIA CHROMOSOME NEGATIVE CELL; PROTEIN EXPRESSION; REVIEW;

EID: 84904617546     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00101     Document Type: Review

References (39)

1. Shah A, Coleman MP. Increasing incidence of childhood leukaemia: a controversy re-examined. Br J Cancer (2007) 97(7):1009-12.
2. Smith MA, Seibel NL, Altekruse SF, Ries LA, Melbert DL, O'Leary M, et al. Outcomes for children and adolescents with cancer: challenges for the twenty-first century. J Clin Oncol (2010) 28(15):2625-34. doi:10.1200/JCO.2009.27.0421
3. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin (2010) 60(5):277-300. doi:10.3322/caac.20073
4. American Cancer Society. Cancer Facts & Figures for African Americans 2011-2012. Atlanta: American Cancer Society (2011).
5. Attia RR, Gardner LA, Mahrous E, Taxman DJ, Legros L, Rowe S, et al. Selective targeting of leukemic cell growth in vivo and in vitro using a gene silencing approach to diminish S-adenosylmethionine synthesis. J Biol Chem (2008) 283(45):30788-95. doi:10.1074/jbc.M804159200
6. Cunningham L, Aplenc R. Pharmacogenetics of acute lymphoblastic leukemia treatment response. Expert Opin Pharmacother (2007) 8(15):2519-31. doi:10.1517/14656566.8.15.2519
7. Kokkinakis DM, Brickner AG, Kirkwood JM, Liu X, Goldwasser JE, Kastrama A, et al. Mitotic arrest, apoptosis, and sensitization to chemotherapy of melanomas by methionine deprivation stress. Mol Cancer Res (2006) 4(8):575-89. doi:10.1158/1541-7786.MCR-05-0240
8. Pui CH, Jeha S. New therapeutic strategies for the treatment of acute lymphoblastic leukaemia. Nat Rev Drug Discov (2007) 6(2):149-65. doi:10.1038/nrd2240
9. van Ginkel PR, Sareen D, Subramanian L, Walker Q, Darjatmoko SR, Lindstrom MJ, et al. Resveratrol inhibits tumor growth of human neuroblastoma and mediates apoptosis by directly targeting mitochondria. Clin Cancer Res (2007) 13(17):5162-9. doi:10.1158/1078-0432.CCR-07-0347
10. Kersey JH. Fifty years of studies of the biology and therapy of childhood leukemia. Blood (1997) 90(11):4243-51.
11. Tyner JW, Jemal AM, Thayer M, Druker BJ, Chang BH. Targeting surviving and p53 in pediatric acute lymphoblastic leukemia. Leukemia (2012) 26(4):623-32. doi:10.1038/leu.2011.249
12. Markman JL, Rekechenetskiy A, Holler E, Ljubimova JY. Nanomedicine therapeutic approaches to overcome cancer drug resistance. Adv Drug Deliv Rev (2013) 65(13-14):1866-79. doi:10.1016/j.addr.2013.09.019
13. Guo D, Wu C, Li X, Jiang H, Wang X, Chen B. In vitro cellular uptake and cytotoxic effect of functionalized nickel nanoparticles on leukemia cancer cells. J Nanosci Nanotechnol (2008) 8(5):2301-7. doi:10.1166/jnn.2008.311
14. Krishnan V, Xu X, Barwe SP, Yang X, Czymmek K, Waldman SA, et al. Dexamethasone-loaded block copolymer nanoparticles induce leukemia cell death and enhance therapeutic efficacy: a novel application in pediatric nanomedicine. Mol Pharm (2013) 10(6):2199-210. doi:10.1021/mp300350e
15. Luo YL, Shiao YS, Huang YF. Release of photoactivatable drugs from plasmonic nanoparticles for targeted cancer therapy. ACS Nano (2011) 5(10):7796-804. doi:10.1021/nn201592s
16. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol (2007) 2(12):751-60. doi:10.1038/nnano.2007.387
17. Zhou Y, Sridhar R, Shan L, Sha W, Gu X, Sukumar S. Loperamide, an FDA-approved antidiarrhea drug, effectively reverses the resistance of multidrug resistant MCF-7/MDR1 human breast cancer cells to doxorubicin-induced cytotoxicity. Cancer Invest (2012) 30(2):119-25. doi:10.3109/07357907.2011.640653
18. Eifler AC, Thaxton CS. Nanoparticle therapeutics: FDA approval, clinical trials, regulatory pathways, and case study. Methods Mol Biol (2011) 726:325-38. doi:10.1007/978-1-61779-052-2_21
19. Badr G, Al-Sadoon MK, Rabah DM. Therapeutic efficacy and molecular mechanisms of snake (Walterinnesia aegyptia) venom-loaded silica nanoparticles in the treatment of breast cancer- and prostate cancer-bearing experimental mouse models. Free Radic Biol Med (2013) 65:175-89. doi:10.1016/j.freeradbiomed.2013.06.018
20. Pui CH, Carroll WL, Meshinchi S, Arceci RJ. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol (2011) 29(5):551-65. doi:10.1200/JCO.2010.30.7405
21. Turner M, Gagnon D, Lagace M, Gagnon I. Effect of treatment for paediatric cancers on balance: what do we know? A review of the evidence. Eur J Cancer Care (Engl) (2013) 22(1):3-11. doi:10.1111/ecc.12019
22. Krishnan V, Rajasekaran AK. Clinical nanomedicine: a solution to the chemotherapy conundrum in pediatric leukemia therapy. Clin Pharmacol Ther (2014) 95(2):168-78. doi:10.1038/clpt.2013.174
23. Sabnis N, Nair M, Israel M, McConathy WJ, Lacko AG. Enhanced solubility and functionality of valrubicin (AD-32) against cancer cells upon encapsulation into biocompatible nanoparticles. Int J Nanomedicine (2012) 7:975-83. doi:10.2147/IJN.S28029
24. Yang S, Damiano MG, Zhang H, Tripathy S, Luthi AJ, Rink JS, et al. Biomimetic, synthetic HDL nanostructures for lymphoma. Proc Natl Acad Sci U S A (2013) 110(7):2511-6. doi:10.1073/pnas.1213657110
25. Mooberry LK, Nair M, Paranjape S, McConathy WJ, Lacko AG. Receptor mediated uptake of paclitaxel from a synthetic high density lipoprotein nanocarrier. J Drug Target (2010) 18(1):53-8. doi:10.3109/10611860903156419
26. Vitols S, Gahrton C, Ost A, Peterson C. Elevated low density lipoprotein receptor activity in leukemic cells with monocytic differentiation. Blood (1984) 63(5):1186-1193.
27. Vitols S, Angelin B, Ericsson S, Gahrton G, Juliusson G, Masquelier M, et al. Uptake of low density lipoproteins by human leukemic cells in vivo: relation to plasma lipoprotein levels and possible relevance for selective chemotherapy. Proc Natl Acad Sci U S A (1990) 87(7):2598-2602. doi:10.1073/pnas.87.7.2598
28. Masquelier M, Tirzitis G, Peterson CO, Pålsson M, Amolins A, Plotniece M, et al. Plasma stability and cytotoxicity of lipophilic daunorubicin derivatives incorporated into low density lipoproteins. Eur J Med Chem (2000) 35(4):429-38. doi:10.1016/S0223-5234(00)00139-2
29. Masquelier M, Vitols S, Pålsson M, Mårs U, Larsson BS, Peterson CO. Low density lipoprotein as a carrier of cytostatics in cancer chemotherapy: study of stability of drug-carrier complexes in blood. J Drug Target (2000) 8(3):155-64. doi:10.3109/10611860008996861
30. Shahzad MM, Mangala LS, Han HD, Lu C, Bottsford-Miller J, Nishimura M, et al. Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles. Neoplasia (2011) 13(4):309-19.
31. Sabnis N, Pratap S, Akopova I, Bowman PW, Lacko AG. Pre-clinical evaluation of rHDL encapsulated retinoids for the treatment of neuroblastoma. Front Pediatr (2013) 1:6. doi:10.3389/fped.2013.00006
32. Nanjee MN, Cooke CJ, Garvin R, Semeria F, Lewis G, Olszewski WL, et al. Intravenous apoA-I/lecithin discs increase pre-beta-HDL concentration in tissue fluid and stimulate reverse cholesterol transport in humans. J Lipid Res (2001) 42:1586-93.
33. Pajkrt D, Lerch PG, van der Poll T, Levi M, Illi M, Doran JE, et al. Differential effects of reconstituted high-density lipoprotein on coagulation, fibrinolysis and platelet activation during human endotoxemia. Thromb Haemost (1997) 77:303-7.
34. Kujiraoka T, Hattori H, Ito M, Nanjee MN, Ishihara M, Nagano M, et al. Effects of intravenous apolipoprotein A-I/phosphatidylcholine discs on paraoxonase and platelet-activating factor acetyl hydrolase in human plasma and tissue fluid. Atherosclerosis (2004) 176:57-62. doi:10.1016/j.atherosclerosis.2004.03.026
35. Tardif JC. Emerging high-density lipoprotein infusion therapies: fulfilling the promise of epidemiology? J Clin Lipidol (2010) 4(5):399-404. doi:10.1016/j.jacl.2010.08.018
36. Muntoni S, Atzori L, Mereu R, Satta G, Macis MD, Congia M, et al. Serum lipoproteins and cancer. Nutr Metab Cardiovasc Dis (2009) 19(3):218-25. doi:10.1016/j.numecd.2008.06.002
37. Moschovi M, Trimis G, Apostolakou F, Papassotiriou I, Tzortzatou-Stathopoulou F. Serum lipid alterations in acute lymphoblastic leukemia of childhood. J Pediatr Hematol Oncol (2004) 26(5):289-93. doi:10.1097/00043426-200405000-00006
38. Scribano D, Baroni S, Pagano L, Zuppi C, Leone G, Giardina B. Return to normal values of lipid after effective chemotherapy in acute lymphoblastic leukemia. Haematologica (1996) 81:343-5.
39. Napper AD, Watson VG. Targeted drug discovery for pediatric leukemia. Front Oncol (2013) 3:170. doi:10.3389/fonc.2013.00170